ROY UYENO: Open Payments
NPI 1710460373 · ANCHORAGE, AK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$885 in 21 payments from 10 companies in 2025. Trend: 2023 $418 · 2024 $713 · 2025 $885
Food & beverage: $852Education: $32
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 8 | $329 |
| Otsuka America Pharmaceutical, Inc. | 4 | $189 |
| Novo Nordisk Inc | 2 | $127 |
| Genentech USA, Inc. | 1 | $111 |
| Ascendis Pharma Endocrinology Inc | 1 | $29 |
| Ardelyx, Inc. | 1 | $27 |
| Alexion Pharmaceuticals, Inc. | 1 | $25 |
| AKEBIA THERAPEUTICS INC | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $10 |
Products named: Vanrafia, Fabhalta, Xolair, Wegovy, Yorvipath, IBSRELA, ULTOMIRIS, VOYXACT.
Industry payments across AK — which companies pay providers there.
